Some 41 patients were evaluated in the study. The results demonstrated a 24% overall response rate with a 73% disease control rate.
Botensilimab was well tolerated, the company said.
Shares of the immuno-oncology company jumped 11% in Wednesday afternoon trading.
Price: 2.06, Change: +0.22, Percent Change: +11.68